For context, weight loss outcomes in trials of currently licensed treatments include approximately 15% with semaglutide 2.4 mg (STEP 1 trial, Wilding et al., NEJM 2021) and approximately 2022% with tirzepatide (SURMOUNT-1 trial, Jastreboff et al., NEJM 2022)
Although GLP-1RAs are well established for treating obesity, type 2 diabetes, and for reducing cardiovascular risk, their potential role in inflammatory diseases such as RA has not been clearly defined
By mimicking both simultaneously, tirzepatide improves glucose control , slows gastric emptying , and reduces appetite
doi: 10.33069/cim.2024.0022 23 Armijo-SnchezABentez CastilloNGarca-VidalELuna ChadidMSalvador BalladaCValls RicartGet al
Science Advances, 9(2), eadd5163.
P.AubertJ